Device-Guided Controlled Breathing as a Treatment for Hypertension

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	October 18, 2006
Recommendation:	This topic was reviewed by the California Technology Assessment Forum on October 18, 2006. It was recommended that daily use of RESPeRATE for device-guided breathing to lower systolic blood pressure as adjunctive treatment for patients with persistently high blood pressure in the Stage I or II range, and who are otherwise healthy, non-pregnant individuals meets CTAF Criteria.
Decision:	Does Meet CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments